-+ 0.00%
-+ 0.00%
-+ 0.00%
CG Oncology Presents Cretostimogene Data Showing 41.8% Complete Response Rate at 24 Months
Share
Listen to the news
CG Oncology Presents Cretostimogene Data Showing 41.8% Complete Response Rate at 24 Months
  • CG Oncology reported cretostimogene significantly improved recurrence-free survival in intermediate-risk and high-grade Ta non-muscle-invasive bladder cancer in PIVOT-006.
  • PIVOT-006 data will support a second biologics license application, anticipated in the second quarter of 2027.
  • Topline PIVOT-006 results are scheduled for presentation at SUO on December 2, 2026.
  • Cretostimogene achieved a 41.8% complete response rate at 24 months in BOND-003 Cohort C, with no grade 3-or-higher treatment-related adverse events.
  • BOND-003 Cohort P recorded 80.4% high-grade event-free survival at nine months, with no treatment-related discontinuations.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending